# Transparency Report for Payments to Members of the Public – 2022

#### Overview

This document contains the methodological note and the transparency data for payments and Transfers of Value (ToV) to members of the public, including patients and journalists, in accordance with the ABPI Code of Practice for the Pharmaceutical Industry (the ABPI Code).

## Methodological Note

Lilly engages with individual members of the UK public to better understand the lived experience of diseases and to help us develop medicines to make life better. Such engagements are undertaken in line with the ABPI Code.

This Methodological Note is intended to serve as supporting documentation for the Lilly Members of the Public Disclosure report, which is published annually. It underlines the rationale for interactions between Lilly and members of the UK public, and describes the methods applied to meet the reporting requirements outlined in the ABPI Code.

Members of the public include patients, caregivers, patient advocates, academic researchers, journalists, bloggers, or government officials. Payments to these groups for contracted services related to healthcare, disease, or medicine, must be disclosed on an aggregate basis, and are published on <a href="Transparency Reports">Transparency Reports</a> | Policies & Reports | Lilly UK each year. Payments to people defined as Healthcare Professionals or Other Relevant Decision Makers in the ABPI Code are reported on <a href="Disclosure UK">Disclosure UK (abpi.org.uk)</a>.

The types of services that are included in the annual disclosure are those related to healthcare, disease or medicine. These include acting as consultants or delivering training, participating in market research, or speaking engagements. Payments for work to support clinical trials are excluded if they fall within the remit of Research and Development payments as defined in Clause 1.20 of the ABPI code, including consultancy specific to a clinical trial or Data Management Committee service. Such payments are reported on Disclosure UK (abpi.org.uk). Lilly does not pay authors of scientific papers.

As required by the ABPI Code, payments to members of the public are reported in the categories of public, patients and journalists. Fees for service are reported separately from expenses for these categories. All qualifying payments to UK members of the public are included.

It should be noted that payments to patient advocates or other individuals who are representatives of Patient Organisations are not included in these figures, as payments for services for these individuals must be made to, and reported as payments to, Patient Organisations, published on <a href="https://link.google.com/lillypad.eu">lillypad.eu</a>.

#### **Cross-Border Transfers of Values**

Lilly defines "Cross-Border Transfers of Value" (ToV) as a ToV to a member of the public where the country from which Lilly funding is being provided is different to the country of the individual beneficiary. These ToVs are disclosed in the country in which the member of the public is resident for the majority of the time in accordance with local requirements.

### **Report Regeneration**

Regarding report corrections, once reports have been published, data corrections may require updates to reports that are publicly available. Once revisions have been made, the publicly available reports may need to be updated to reflect the changes.

**Published Date:** The publication date equals the date the report is generated via internal systems.

This data will remain published for three years in the public domain as required by the ABPI Code.

# Transparency Data for 2022

Please refer to the methodological note section for definitions of the categories used in the table below.

	Fees for Contracted Services	Expenses	Number of Individuals in this category	Description of the Types of Services
Payments to Patients	£3230	0	11	Advising and Consulting, Speaking, Market Research
Payments to Journalists	0	0	0	Not applicable
Payments to Other Members of the Public	£45,190	£17,513	25	Academic Collaboration including Advising and Consulting, Speaking, and Chairing Meetings, and not related to specific clinical trial research.